Aliases & Classifications for Brain Edema

MalaCards integrated aliases for Brain Edema:

Name: Brain Edema 12 54 43 15 17 71
Intracranial Swelling 12
Cerebral Edema 71
Wet Brain 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4724
MeSH 43 D001929
SNOMED-CT 67 2032001 85974009
UMLS 71 C0006114 C1527311

Summaries for Brain Edema

Disease Ontology : 12 A brain disease that is characterized by excess accumulation of fluid in the intracellular and/or extracellular spaces of the brain, has symptom nausea, has symptom vomiting, has symptom blurred vision, has symptom seizure, has symptom coma.

MalaCards based summary : Brain Edema, also known as intracranial swelling, is related to hydrops, lactic acidosis, and sideroblastic anemia and traumatic brain injury, and has symptoms including vomiting, coma and blurred vision. An important gene associated with Brain Edema is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Pathways in cancer. The drugs Nicardipine and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and endothelial, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 74 Cerebral edema is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of... more...

Related Diseases for Brain Edema

Diseases related to Brain Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 hydrops, lactic acidosis, and sideroblastic anemia 32.6 VEGFA MIP KNG1 AQP4 ALB
2 traumatic brain injury 31.9 MMP9 IL6 AQP4
3 intracranial hypertension 31.5 IL1B AQP4 AQP1 ALB
4 ischemia 31.0 VEGFA SOD1 SLC1A2 KNG1 HMOX1
5 meningoencephalitis 31.0 IL6 CLDN5 ALB
6 hepatic encephalopathy 30.8 SLC25A13 SLC1A2 MMP9 IL6 GLUL AQP4
7 stroke, ischemic 30.8 SLC1A2 MMP9 IL6 AQP4 ALB
8 arteriovenous malformation 30.8 VEGFA MMP9 IL6
9 bacterial meningitis 30.8 MMP9 IL6 IL1B AQP4 ALB
10 meningitis 30.7 VEGFA MMP9 IL6 IL1B AQP4 ALB
11 encephalitis 30.7 TJP1 IL6 IL1B AQP4
12 spinal cord injury 30.7 MMP9 IL6 AQP4
13 end stage renal failure 30.5 SOD1 IL6 BDKRB2 ALB
14 proteasome-associated autoinflammatory syndrome 1 30.5 MMP9 IL6 IL1B ALB
15 arteriovenous malformations of the brain 30.4 VEGFA MMP9 IL6
16 exanthem 30.3 VEGFA IL6 ALB
17 dysentery 30.3 IL6 IL1B ALB
18 encephalomalacia 30.2 SLC1A2 IL6 IL1B
19 neuroma 30.2 IL6 AQP4 AQP1
20 demyelinating disease 30.1 MMP9 IL6 IL1B AQP4
21 migraine with or without aura 1 29.9 SLC1A2 KNG1 IL6 IL1B ALB
22 peripheral nervous system disease 29.9 VEGFA SOD1 IL6 IL1B AQP4 ALB
23 vascular disease 29.6 VEGFA SOD1 MMP9 KNG1 IL6 HMOX1
24 malaria 29.6 VEGFA TJP1 SOD1 MMP9 IL6 IL1B
25 pre-eclampsia 29.2 VEGFA SOD1 MMP9 KNG1 IL6 IL1B
26 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1 12.7
27 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 12.6
28 citrullinemia, type ii, adult-onset 11.2
29 encephalopathy, acute, infection-induced 4 11.2
30 mitochondrial complex i deficiency, nuclear type 20 11.0
31 brain injury 10.7
32 cerebral artery occlusion 10.6
33 meningitis and encephalitis 10.6 SOD1 ALB
34 dysferlinopathy 10.6 MIP AQP4 AQP1
35 background diabetic retinopathy 10.6 VEGFA IL6 ALB
36 hantavirus hemorrhagic fever with renal syndrome 10.6 VEGFA IL6 ALB
37 inappropriate adh syndrome 10.6 AQP4 AQP1 ALB
38 intestinal perforation 10.6 VEGFA IL6 ALB
39 blood group, globoside system 10.6 VEGFA IL6 ALB
40 impaired renal function disease 10.6 MIP AQP4 AQP1
41 acute transverse myelitis 10.6 MMP9 IL6 AQP4
42 transverse myelitis 10.6 MMP9 IL6 AQP4
43 myelitis 10.6 MMP9 IL6 AQP4
44 endophthalmitis 10.6 VEGFA IL6 ALB
45 intussusception 10.6 VEGFA IL6 ALB
46 communicating hydrocephalus 10.6 AQP4 AQP1 ALB
47 chronic ulcer of skin 10.6 VEGFA IL6 ALB
48 persistent fetal circulation syndrome 10.6 VEGFA IL6 ALB
49 pulmonary artery disease 10.6 VEGFA IL6 ALB
50 acute liver failure 10.6

Comorbidity relations with Brain Edema via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Cancer
Brain Compression Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Hypertension, Essential

Graphical network of the top 20 diseases related to Brain Edema:



Diseases related to Brain Edema

Symptoms & Phenotypes for Brain Edema

Symptoms:

12
  • vomiting
  • coma
  • blurred vision
  • nausea
  • seizure

UMLS symptoms related to Brain Edema:


edema, headache, peau d'orange

MGI Mouse Phenotypes related to Brain Edema:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 AQP1 AQP4 BDKRB2 GLUL HMOX1 IL6
2 cardiovascular system MP:0005385 10.3 ALB AQP1 AQP4 BDKRB2 CLDN5 GLUL
3 homeostasis/metabolism MP:0005376 10.22 ALB AQP1 AQP4 BDKRB2 GLUL HMOX1
4 growth/size/body region MP:0005378 10.21 AQP1 AQP4 GLUL HMOX1 IL1B IL6
5 cellular MP:0005384 10.17 ALB BDKRB2 GLUL HMOX1 IL6 MMP9
6 endocrine/exocrine gland MP:0005379 10.06 ALB AQP1 AQP4 BDKRB2 HMOX1 IL6
7 mortality/aging MP:0010768 10.06 ALB AQP1 AQP4 BDKRB2 CLDN5 GLUL
8 liver/biliary system MP:0005370 9.86 ALB GLUL HMOX1 IL6 OTC SLC25A13
9 nervous system MP:0003631 9.77 AQP1 AQP4 CLDN5 GLUL IL1B IL6
10 renal/urinary system MP:0005367 9.36 ALB AQP1 AQP4 BDKRB2 HMOX1 IL6

Drugs & Therapeutics for Brain Edema

Drugs for Brain Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
5
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
6 Narcotics Phase 4
7 Analgesics, Opioid Phase 4
8 diuretics Phase 4
9 Carbonic Anhydrase Inhibitors Phase 4
10 Hormone Antagonists Phase 4
11 Progestins Phase 4
12 Pharmaceutical Solutions Phase 4
13 Natriuretic Agents Phase 4
14 Arginine Vasopressin Phase 4
15 Vasopressins Phase 4
16
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
17
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
18
Misoprostol Approved Phase 3 59122-46-2 5282381
19
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
20
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
21
Glyburide Approved Phase 3 10238-21-8 3488
22
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
24
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
25 Tocotrienol Investigational Phase 3 6829-55-6
26 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
27 Anesthetics, General Phase 2, Phase 3
28 Anesthetics, Intravenous Phase 2, Phase 3
29 3-n-butylphthalide Phase 3
30 Platelet Aggregation Inhibitors Phase 3
31 Tocopherols Phase 3
32 Tocotrienols Phase 3
33 Alpha-lipoic Acid Phase 3
34 Thioctic Acid Phase 3
35 Anti-Ulcer Agents Phase 3
36 Antacids Phase 3
37 Oxytocics Phase 3
38 Hypoglycemic Agents Phase 3
39 Tissue Plasminogen Activator Phase 2, Phase 3
40 Artemisinins Phase 3
41 Artemisinine Phase 3
42 Protective Agents Phase 3
43 Neuroprotective Agents Phase 3
44 Cardiac Glycosides Phase 3
45
leucovorin Approved Phase 2 58-05-9 6006 143
46
Ibuprofen Approved Phase 2 15687-27-1 3672
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
49
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
50
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
2 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
3 Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy Completed NCT02037815 Phase 4 20% mannitol solution, 125 ml, IV infusion in 15 min;3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
4 Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study Completed NCT01809639 Phase 4 Progesterone;Placebo
5 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Low Dose Acetazolamide;Normal Dose Acetazolamide
6 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
7 Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate Completed NCT01692769 Phase 4 Normal Saline;Ringer's Lactate
8 Effect of Isosmotic Doses of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation in Supratentorial Craniotomies Recruiting NCT03573999 Phase 4 Mannitol;NaCl 7.5%
9 An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke Not yet recruiting NCT04143880 Phase 4 Progesterone
10 A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit Suspended NCT03066440 Phase 4 Normal saline;Lactated Ringers
11 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
12 Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury Withdrawn NCT01526876 Phase 4 clevidipine butyrate
13 High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury Unknown status NCT00152685 Phase 2, Phase 3 human serum albumin
14 Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury. Unknown status NCT03285165 Phase 2, Phase 3 0.2-0.7 mcg/kg/h dexmedetomedine infusion.;10-70 mcg/kg/h propofol infusion.
15 Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis Completed NCT01365793 Phase 3 0.45% saline replacement fluid;0.9% saline replacement fluid;0.45% saline intravenous fluid;0.9% saline Intravenous fluid
16 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Completed NCT00088166 Phase 3 hCRF;placebo hCRF
17 An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
18 Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Completed NCT01405248 Phase 3 Butylphthalide;Placebo
19 Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards? Completed NCT00347477 Phase 3 HyperHAES vs. RA-solution/NaCl
20 Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial Completed NCT01556646 Phase 3 Tolvaptan
21 Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness. Completed NCT00664001 Phase 3
22 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
23 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
24 Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy and Carotid Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591005 Phase 3
25 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction Recruiting NCT02864953 Phase 3 BIIB093;Placebo
26 Salovum (Antisecretory Factor) in Patients With Severe Traumatic Brain Injury Recruiting NCT03339505 Phase 3
27 Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study Recruiting NCT03284463 Phase 2, Phase 3 Glibenclamide;Placebo
28 Treating Brain Swelling in Pediatric Cerebral Malaria Recruiting NCT03300648 Phase 3
29 Efficacy and Safety of Neuroprotectant Cattle Encephalon Glycoside and Ignotin Injection for Intracerebral Hemorrhage: a Multicenter, Randomized, Double-blinded, Placebo-controlled Trial. Not yet recruiting NCT03546283 Phase 3 Placebos;Cattle Encephalon Glycoside and Ignotin
30 Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts : A Sequential Design, Multicenter, Randomized, Controlled Trial Terminated NCT00190203 Phase 3
31 Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ? Terminated NCT00159926 Phase 3
32 A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
33 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
34 Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding Unknown status NCT01830894 Phase 1, Phase 2
35 Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage Unknown status NCT01866384 Phase 2
36 Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
37 Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury Unknown status NCT02443142 Phase 2 Ibuprofen;Acetaminophen
38 High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
39 Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review Completed NCT03276494 Phase 2 Hypertonic saline
40 Comparison of Balanced Crystalloid Solution and 0,9% Sodium Chloride in Children Undergoing Brain Tumor Resection: a Randomized Controlled Trial Completed NCT02707549 Phase 2 balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride);0.9% sodium chloride
41 Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke Completed NCT01428401 Phase 2 Chinese Herb Astragalus membranaceus
42 Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator Completed NCT00777140 Phase 2 Deferoxamine
43 A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme Completed NCT00047073 Phase 1, Phase 2 Rapamycin
44 Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. Completed NCT02142712 Phase 2 Diphenhydramine;Pantoprazole;Famotidine;Dextromethorphan
45 Hypothermia Treatment in Hyperammonemia and Encephalopathy Completed NCT01624311 Phase 2
46 A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury Completed NCT01548690 Phase 2 Ornithine Phenylacetate
47 PET Imaging of Translocator Protein in Subjects With Traumatic Brain Injury Completed NCT01547780 Phase 1, Phase 2
48 A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury Completed NCT00973674 Phase 2 Premarin IV;Placebo
49 A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed NCT02157103 Phase 2 Bevacizumab 25 mg in 1 ml subcutaneously daily
50 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]

Search NIH Clinical Center for Brain Edema

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dexamethasone
dexamethasone acetate
DEXAMETHASONE ACETATE PWDR
Dexamethasone phosphate
Dexamethasone sodium phosphate
DEXAMETHASONE SODIUM PHOSPHATE PWDR
Mannitol
Mannitol hexanitrate
MANNITOL PWDR

Cochrane evidence based reviews: brain edema

Genetic Tests for Brain Edema

Anatomical Context for Brain Edema

MalaCards organs/tissues related to Brain Edema:

40
Brain, Liver, Endothelial, Lung, Cortex, Bone, Neutrophil

Publications for Brain Edema

Articles related to Brain Edema:

(show top 50) (show all 6590)
# Title Authors PMID Year
1
Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. 54 61
20168229 2010
2
Aquaporin-4 and traumatic brain edema. 54 61
20356447 2010
3
Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. 54 61
20217200 2010
4
[Regulation, structure and function of brain aquaporin]. 54 61
20030210 2009
5
[AQP4 expression in the brains of patients with glioblastoma and its association with brain edema]. 54 61
19764565 2009
6
Roles of aquaporin-4 isoforms and amino acids in square array assembly. 54 61
19445480 2009
7
Role of bradykinin and catecholamines in cerebral infarction and brain edema. 54 61
19265042 2009
8
Acetazolamide reversibly inhibits water conduction by aquaporin-4. 54 61
19114109 2009
9
Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury. 54 61
19429018 2009
10
Actin cytoskeleton remodeling governs aquaporin-4 localization in astrocytes. 54 61
18649401 2008
11
[The relationship between the aquaporin-4 and brain edema, pathologic change, ultrastructure in peri-hematoma tissue in patients with intracerebral hemorrhage]. 54 61
19000426 2008
12
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides. 54 61
18572411 2008
13
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage. 54 61
18442833 2008
14
High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. 54 61
18436890 2008
15
The role of aquaporin-4 polymorphisms in the development of brain edema after middle cerebral artery occlusion. 54 61
18309154 2008
16
Aquaporin-4 in hepatic encephalopathy. 54 61
17879149 2007
17
Can variation in aquaporin 4 gene be associated with different outcomes in traumatic brain edema? 54 61
17890008 2007
18
Aquaporins: multiple roles in the central nervous system. 54 61
17901256 2007
19
Temporal and regional evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pup model of neonatal stroke. 54 61
17622964 2007
20
Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. 54 61
17335082 2007
21
Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis. 54 61
17454447 2007
22
Aquaporins as targets for drug discovery. 54 61
17692010 2007
23
Control of brain glutamine synthesis by NMDA receptors. 54 61
17127345 2007
24
[Personal recollection of episodes devoted to my study of neuropathology]. 54 61
17432177 2006
25
Astrocyte end-feet in germinal matrix, cerebral cortex, and white matter in developing infants. 54 61
16627880 2006
26
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion. 54 61
16671493 2006
27
Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. 54 61
16211562 2005
28
[Brain edema and aquaporin]. 54 61
16313100 2005
29
Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. 54 61
16133546 2005
30
Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. 54 61
15815585 2005
31
Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. 54 61
15772982 2005
32
[Protective effects of total paeony glycoside against global cerebral ischemia-reperfusion injury in gerbils]. 54 61
15837661 2005
33
Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adult-onset type II citrullinemia (CTLN2). 54 61
15805705 2005
34
In vivo expression of aquaporin-4 by reactive microglia. 54 61
15525343 2004
35
Molecular mechanisms and drug development in aquaporin water channel diseases: structure and function of aquaporins. 54 61
15557734 2004
36
Aquaporin water channels in central nervous system. 54 61
16181079 2004
37
Aquaporins and brain edema. 54 61
15120208 2004
38
Alpha-syntrophin deletion removes the perivascular but not endothelial pool of aquaporin-4 at the blood-brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. 54 61
14734638 2004
39
Importance of aquaporins in the physiopathology of brain edema. 54 61
15281891 2004
40
Regulation of brain aquaporins. 54 61
15561410 2004
41
Aquaporin water channels: molecular mechanisms for human diseases. 54 61
14630322 2003
42
Enhanced expression of aquaporin 4 in human brain with infarction. 54 61
12715185 2003
43
Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. 54 61
12824287 2003
44
[Relationship between aquaporin-4 expression in astrocytes and brain edema caused by glioma]. 54 61
12810377 2003
45
Testosterone up-regulates aquaporin-4 expression in cultured astrocytes. 54 61
12774311 2003
46
Therapeutical efficacy of a novel non-peptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia. 54 61
14753436 2003
47
Pathophysiology of traumatic brain edema: current concepts. 54 61
14753394 2003
48
Bench to bedside: brain edema and cerebral resuscitation: the present and future. 54 61
12208684 2002
49
Aquaporins in the central nervous system. 54 61
11115728 2001
50
Lipocortin-1 fails to ameliorate cold-injury brain edema in the rat. 54 61
11450032 2000

Variations for Brain Edema

Expression for Brain Edema

Search GEO for disease gene expression data for Brain Edema.

Pathways for Brain Edema

Pathways related to Brain Edema according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13 MMP9 KNG1 IL6 IL1B CLDN5 BDKRB2
2 12.52 VEGFA MMP9 KNG1 IL6 HMOX1 BDKRB2
3
Show member pathways
12.19 SOD1 IL6 IL1B ALB
4 12.14 TJP1 IL6 IL1B CLDN5
5 12.02 VEGFA IL6 IL1B AQP4
6 11.94 VEGFA MMP9 IL1B HMOX1
7
Show member pathways
11.81 SOD1 MMP9 IL6 IL1B
8 11.66 TJP1 IL6 IL1B
9 11.59 MMP9 IL6 IL1B
10 11.43 MMP9 IL6 IL1B AQP4 AQP1
11 11.38 MMP9 KNG1 IL6
12
Show member pathways
11.36 VEGFA MMP9 IL6 IL1B
13 11.26 MMP9 IL6 IL1B HMOX1
14 11.22 KNG1 IL6 IL1B
15 11.18 SOD1 IL6 IL1B
16 11.15 IL6 IL1B HMOX1
17 11.08 MMP9 IL6 HMOX1
18 11.08 VEGFA MMP9 IL6 IL1B HMOX1
19
Show member pathways
10.45 SLC1A2 GLUL

GO Terms for Brain Edema

Cellular components related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VEGFA SOD1 NAXE MMP9 KNG1 IL6
2 cell GO:0005623 9.7 SOD1 KNG1 IL6 HMOX1 BDKRB2 AQP4
3 extracellular space GO:0005615 9.28 VEGFA SOD1 NAXE MMP9 KNG1 IL6
4 platelet alpha granule lumen GO:0031093 9.13 VEGFA KNG1 ALB

Biological processes related to Brain Edema according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.88 SOD1 MMP9 KNG1 IL6 HMOX1
2 negative regulation of apoptotic process GO:0043066 9.8 VEGFA SOD1 MMP9 IL6 AQP1 ALB
3 response to drug GO:0042493 9.77 TJP1 SOD1 SLC1A2 OTC AQP1
4 positive regulation of angiogenesis GO:0045766 9.76 VEGFA IL1B HMOX1 AQP1
5 cytokine-mediated signaling pathway GO:0019221 9.65 VEGFA MMP9 IL6 IL1B HMOX1
6 embryo implantation GO:0007566 9.61 SOD1 MMP9 IL1B
7 cellular response to cadmium ion GO:0071276 9.58 SOD1 MMP9 HMOX1
8 regulation of bicellular tight junction assembly GO:2000810 9.55 TJP1 CLDN5
9 positive regulation of neuroinflammatory response GO:0150078 9.54 IL6 IL1B
10 positive regulation of chemokine biosynthetic process GO:0045080 9.52 IL1B HMOX1
11 regulation of neuroinflammatory response GO:0150077 9.51 MMP9 IL6
12 multicellular organismal water homeostasis GO:0050891 9.49 AQP4 AQP1
13 platelet degranulation GO:0002576 9.46 VEGFA SOD1 KNG1 ALB
14 nicotinamide nucleotide metabolic process GO:0046496 8.96 NAXE NAXD
15 water transport GO:0006833 8.8 MIP AQP4 AQP1

Molecular functions related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 9.37 SLC25A13 SLC1A2
2 channel activity GO:0015267 9.33 MIP AQP4 AQP1
3 NADPHX epimerase activity GO:0052857 9.32 NAXE NAXD
4 identical protein binding GO:0042802 9.28 VEGFA SOD1 SLC25A13 NAXE MMP9 GLUL
5 NADHX epimerase activity GO:0052856 9.26 NAXE NAXD
6 water channel activity GO:0015250 9.13 MIP AQP4 AQP1

Sources for Brain Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....